

Vizimpro[®] (dacomitinib) (Oral)

Document Number: IC-0397

Last Review Date: 07/05/2022

Date of Origin: 10/30/2018

Dates Reviewed: 11/2018, 07/2019, 07/2020, 07/2021, 07/2022

I. Length of Authorization

Coverage will be provided for 6 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Vizimpro 15 mg tablets: 1 tablet per day
- Vizimpro 30 mg tablets: 1 tablet per day
- Vizimpro 45 mg tablets: 1 tablet per day

B. Max Units (per dose and over time) [HCPCS Unit]:

- 45 mg daily

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

Universal Criteria ¹

- Patient will avoid coadministration with proton-pump inhibitors (PPIs), or if acid-reduction therapy is required, use of H₂-receptor antagonists or antacids may be used at staggered administration times; **AND**
- Used as single agent-therapy; **AND**

Non-Small Cell Lung Cancer † Φ ¹⁻³

- Patient has recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease without evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation therapy; **AND**
- Patient has one of the following molecular mutations as confirmed by an FDA-approved or CLIA-compliant test❖: EGFR exon 19 deletion, EGFR exon 21 L858R substitution, or EGFR S768I, L861Q, and/or G719X mutation positive tumors; **AND**

- Used as first-line therapy; **OR**
- Used as continuation of therapy following disease progression on dacomitinib for asymptomatic disease, symptomatic brain lesions, or symptomatic systemic limited* metastases †; **AND**
 - Used for T790M mutation-negative disease

*Limited number is undefined but clinical trials have included 3 to 5 metastases.

❖ If confirmed using an immunotherapy assay-<http://www.fda.gov/companiondiagnostics>

† FDA Approved Indication(s); ‡ Compendia recommended indication(s); Ⓢ Orphan Drug

IV. Renewal Criteria ¹

Coverage can be renewed based upon the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in Section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: interstitial lung disease, severe/persistent diarrhea, and dermatologic adverse reactions (e.g., rash, exfoliative skin reactions), etc.; **AND**
 - Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **OR**
 - For continuation therapy following dacomitinib progression, disease response is defined as lack of continued disease progression, improvement in tumor size, or improvement in patient symptoms

V. Dosage/Administration ¹

Indication	Dose
Non-Small Cell Lung Cancer	Recommended starting dosage is 45 mg orally once daily until disease progression or unacceptable toxicity occurs.

VI. Billing Code/Availability Information

HCPCS Code:

- J8999 – Prescription drug, oral, chemotherapeutic, NOS
- C9399 – Unclassified drugs or biologicals (*Hospital Outpatient Use ONLY*)

NDC:

- Vizimpro 15 mg tablets: 00069-0197-xx
- Vizimpro 30 mg tablets: 00069-1198-xx
- Vizimpro 45 mg tablets: 00069-2299-xx

VII. References

1. Vizimpro [package insert]. New York, NY; Pfizer Labs; December 2020. Accessed June 2022.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for dacomitinib. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed June 2022.
3. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.

Appendix 1 – Covered Diagnosis Codes

ICD-10	Description
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
Z85.118	Personal history of other malignant neoplasm of bronchus and lung

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/ LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto Government Benefit Administrators, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC